Regenerative research✎ Written by Claude — not in notes✎ Written by Claude — not in notesSection label written by Claude. Not from client notes.
Tissue Repair & Recovery✓ From client notes✓ From client notesCategory name + compounds are from the client's peptide category table (provided in chat: 'Common Uses & Types of Peptide Therapy'). Factual grouping, not a claim.
Peptides studied in the context of soft-tissue recovery — tendons, ligaments, and the healing cascade.✎ Written by Claude — not in notes✎ Written by Claude — not in notesWritten by Claude (hedged summary). Not from client notes. Replace/confirm with client copy.
Commonly discussed· Standard UI· Standard UISection label written by Claude. Not from client notes.
BPC-157, TB-500✓ From client notes✓ From client notesCategory name + compounds are from the client's peptide category table (provided in chat: 'Common Uses & Types of Peptide Therapy'). Factual grouping, not a claim.
Peptides studied in the context of soft-tissue recovery — tendons, ligaments, and the healing cascade.✎ Written by Claude — not in notes✎ Written by Claude — not in notesWritten by Claude (hedged summary). Not from client notes. Replace/confirm with client copy.
Explored for tendon, ligament & soft-tissue recovery✎ Written by Claude — not in notes✎ Written by Claude — not in notesWritten by Claude (hedged summary). Not from client notes. Replace/confirm with client copy.
Why it matters
Staying active and moving well is what tissue-recovery research is ultimately in service of.✎ Written by Claude — not in notes✎ Written by Claude — not in notesWritten by Claude. General aspirational framing tied to the research area — not a claim that any person achieved this using a specific compound.
Lifestyle photography — general mood imagery, not a patient photo or a documented result.✎ Written by Claude — not in notes✎ Written by Claude — not in notesGeneric AI-generated lifestyle/mood photography, written by Claude. This is NOT a patient, NOT a before/after, and NOT documentation of anyone's result from taking any compound — deliberately excluded per compliance guardrails (see 8015 todo list). It illustrates the research area's real-world goal, nothing more.
— The science, plainly✎ Written by Claude — not in notes✎ Written by Claude — not in notesSection heading written by Claude. Not from client notes.
What it is✎ Written by Claude — not in notes✎ Written by Claude — not in notesSection label written by Claude ('What it is' / 'What research explores' / 'Regulatory status'). Not from client notes.
BPC-157 is a synthetic 15-amino-acid peptide originally derived from a protein found in gastric juice. TB-500 is a synthetic version of a fragment of thymosin beta-4, a naturally occurring protein involved in cell repair and migration.⌕ From research⌕ From researchWritten by Claude from web research (Aug 2026): peer-reviewed/mechanism sources on these compounds. Hedged and educational — NOT from the client notes and NOT an efficacy claim. Verify with primary literature before launch.
What research explores✎ Written by Claude — not in notes✎ Written by Claude — not in notesSection label written by Claude ('What it is' / 'What research explores' / 'Regulatory status'). Not from client notes.
Preclinical research (largely in animal models) describes BPC-157 promoting angiogenesis — new blood-vessel growth — and tendon-fibroblast migration via the FAK-paxillin pathway, and both peptides appear to shift immune cells from a pro-inflammatory to a repair-oriented state. Human clinical evidence is limited, and much of the work to date is early-stage.⌕ From research⌕ From researchWritten by Claude from web research (Aug 2026): peer-reviewed/mechanism sources on these compounds. Hedged and educational — NOT from the client notes and NOT an efficacy claim. Verify with primary literature before launch.
Regulatory status✎ Written by Claude — not in notes✎ Written by Claude — not in notesSection label written by Claude ('What it is' / 'What research explores' / 'Regulatory status'). Not from client notes.
Not FDA-approved for human use. BPC-157 was removed from the FDA's 503A compounding list in 2023 pending further safety data. Availability and legality vary — your provider and their pharmacy confirm what can actually be prescribed before anything proceeds.⌕ From research⌕ From researchWritten by Claude from web research (Aug 2026): peer-reviewed/mechanism sources on these compounds. Hedged and educational — NOT from the client notes and NOT an efficacy claim. Verify with primary literature before launch.
This page is general educational background, not medical advice or an offer to sell any compound. Statements here have not been evaluated by the FDA. Whether any therapy is appropriate for you is determined solely by an independent licensed provider.~ Adapted from notes~ Adapted from notesAdapted from the client's disclaimer intent (TELEGRAMNOTES.md: 'This is not FDA approved, using at your own research and you are responsible...'). Rewritten by Claude for the licensed-provider model — NOT the client's exact research-use-only wording. Needs client + legal sign-off.